|
|
|
|
|
|
|
|
|
|
||||||
|
|
Merck Serono |
|||||||||||||
|
€ million |
Q3 – 2013 reported |
Product group transfer adjustments |
Disclosure change1 |
Q3 – 2013 adjusted |
Jan.–Sept. 2013 reported |
Product group transfer adjustments |
Disclosure change1 |
Jan.–Sept. 2013 adjusted |
||||||
|
||||||||||||||
|
Sales |
1,483.0 |
–70.2 |
– |
1,412.8 |
4,468.2 |
–199.1 |
– |
4,269.1 |
||||||
|
Royalty, license and |
85.1 |
– |
– |
85.1 |
271.4 |
– |
– |
271.3 |
||||||
|
Total revenues |
1,568.1 |
–70.2 |
– |
1,497.9 |
4,739.5 |
–199.1 |
– |
4,540.5 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Cost of sales1 |
–267.2 |
16.8 |
– |
–250.4 |
–799.1 |
60.4 |
– |
–738.8 |
||||||
|
(of which: amortization of intangible assets)1 |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
||||||
|
Gross profit |
1,301.0 |
–53.5 |
– |
1,247.5 |
3,940.4 |
–138.7 |
– |
3,801.7 |
||||||
|
Marketing and selling expenses1 |
–300.6 |
16.6 |
–143.7 |
–427.8 |
–964.7 |
53.7 |
–453.6 |
1,364.6 |
||||||
|
(of which: amortizationof intangible assets)1 |
(–) |
(–) |
(–143.7) |
(–143.7) |
(–) |
(–) |
(–453.6) |
(–453.6) |
||||||
|
Royalty, license and |
–139.4 |
0.1 |
– |
–139.3 |
–422.7 |
0.3 |
– |
–422.4 |
||||||
|
Administration expenses |
–51.0 |
1.7 |
– |
–49.3 |
–154.3 |
5.2 |
– |
–149.2 |
||||||
|
Other operating expenses and income |
–94.4 |
–0.6 |
– |
–95.0 |
–275.2 |
–0.6 |
– |
–275.8 |
||||||
|
Research and development costs |
–297.4 |
1.7 |
– |
–295.7 |
–917.6 |
5.0 |
– |
–912.7 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Operating result (EBIT) |
274.5 |
–34.0 |
– |
240.5 |
752.2 |
–75.1 |
– |
677.1 |
||||||
|
Depreciation and amortization |
190.6 |
– |
– |
190.6 |
606.6 |
– |
– |
606.6 |
||||||
|
Impairment losses |
14.7 |
– |
– |
14.7 |
48.6 |
– |
– |
48.6 |
||||||
|
Reversals of impairment losses |
– |
– |
– |
– |
–0.3 |
– |
– |
–0.3 |
||||||
|
EBITDA |
479.8 |
–34.0 |
– |
445.8 |
1,407.0 |
–75.1 |
– |
1,331.8 |
||||||
|
One-time items |
21.6 |
– |
– |
21.6 |
48.1 |
– |
– |
48.1 |
||||||
|
EBITDA pre one-time items (Segment result) |
501.4 |
–34.0 |
– |
467.4 |
1,455.1 |
–75.1 |
– |
1,379.9 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
EBITDA margin pre one-time items (% of sales) |
33.8 |
|
|
33.1 |
32.6 |
|
|
32.3 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Net operating assets2 |
|
|
|
|
6,968.0 |
–77.3 |
– |
6,890.7 |
||||||
|
Segment liabilities2 |
|
|
|
|
–1,358.0 |
– |
– |
–1,358.0 |
||||||
|
Investments in property, plant and equipment3 |
38.1 |
– |
– |
38.1 |
84.9 |
– |
– |
84.9 |
||||||
|
Investments in intangible assets3 |
7.5 |
– |
– |
7.5 |
48.0 |
– |
– |
48.0 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Net cash flows from operating activities3 |
549.7 |
–21.2 |
– |
528.5 |
1,326.6 |
–57.9 |
– |
1,268.7 |
||||||
|
Business free cash flow |
536.6 |
–24.6 |
– |
512.0 |
1,402.0 |
–64.3 |
– |
1,337.7 |
||||||